. 2023 Feb 13;29(4):486–517. doi: 10.1093/humupd/dmad002

Table I.

Anti-Müllerian hormone and antral follicle count in childhood or adolescent females diagnosed with Hodgkin lymphoma.

Study	N patients	Age at diagnosis	Age at time of study	Follow-up	Treatment	Outcome
Study	N patients	(years)	(years)	(years)	Treatment	Outcome
*Pre-treatment*
van Dorp et al., 2014	32	6.6 (0–17.4)	NA	NA	NA	Pre-treatment, n = 9/32 (28%) patients with low AMH (i.e. <p10 percentile of healthy controls)
*Post-treatment*
Charpentier et al., 2014	29	11.9 (1.8–17.3)	23.3 (18.2–34.2)	11.5 (1.4–25.1)^*	Chemo: n.s.	n = 16/29 (55%) females with low AMH (i.e. <14 pmol/l)
Charpentier et al., 2014	29	11.9 (1.8–17.3)	23.3 (18.2–34.2)	11.5 (1.4–25.1)^*	No pelvic RT	n = 16/29 (55%) females with low AMH (i.e. <14 pmol/l)
van Beek et al., 2007b	30	14.0 (5.0–17.2)	25 (19.2–40.4)	11.6 (5.7–24.5)	Chemo: ABVD, EBVD, MOPP	n = 10/17 (59%) patients with low AMH (i.e. <95% CI of healthy controls)
van Beek et al., 2007b	30	14.0 (5.0–17.2)	25 (19.2–40.4)	11.6 (5.7–24.5)	No pelvic RT	Survivors without MOPP had higher AMH levels compared to survivors treated with MOPP (1.40 ug/l vs 0.39 ug/l, P = 0.01) All women with increased FSH levels had decreased AMH levels
*Decrease in AMH or AFC pre-/post* -*treatment*
Berjeb et al., 2020	32	21.6 ± 4.4	n.s.	(1.3–1.5)	Chemo: BEACOPP, DHAOX, ABVD	Significant decrease in AMH before and after chemotherapy. 2.30 ± 1.96 and 1.54±1.96 ng/ml; P = 0.002
Berjeb et al., 2020	32	21.6 ± 4.4	n.s.	(1.3–1.5)	No pelvic RT	In n = 7/32 (22%) women, AMH values were higher after chemotherapy, when compared to AMH values pre-treatment
Krawczuk-Rybak et al., 2013a	13	14 ± 3.45	20.1 ± 3.5	(6–10)	Chemo: MVPP + BDOPA	Significant decrease in AMH before and after treatment 2.96 ng/ml ± 2.05 and 1.26 ng/ml ± 0.84, P = 0.001
Krawczuk-Rybak et al., 2013a	13	14 ± 3.45	20.1 ± 3.5	(6–10)	Pelvic RT: n = 8/13 (62%), 15 Gy
Policiano et al., 2020	44	22.6 (IQR 18.8–26.4)	n.s.	2.8	Chemo: ABVD	Decrease in AMH before and after treatment 2.2 ng/ml (IQR 1.4–4.4 ng/ml) and 1.3 ng/ml (IQR 0.9–2.5 ng/ml), P not given
					No pelvic RT	Decrease in AFC before and after treatment 19 (IQR 14–23), and 10 (IQR 7–15), P not given
						Patients with AFC <6 or AMH <0.84 ng/ml at baseline were excluded

Follow-up period defined as years off treatment.

ABVD, Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine; AMH, anti-Müllerian hormone; AFC, antral follicle count; BDOPA, Bleomycin, Dacarbazine, Vincristine (Oncovin), Adriamycin, Prednisone; BEACOPP, Bleomycin, Etoposide, Adiamycin (Doxorubicin), Cyclophosphamide, Vincristine (Oncovin), Procarbazine, Prednisone; Chemo, chemotherapy; DHAOX, Dexamethasone, high-dose Cytarabine, and Oxaliplatin; EBVD, Epirubicin, Bleomycin, Vinblastine, Dacarbazine; Gy, Gray; IQR, interquartile range; MOPP, Mechlorethamine, Vincristine (Oncovin), Procarbazine, Prednisone; MVPP, Mechlorethamine, Vinblastine, Procarbazine, Prednisone; NA, not applicable; n.s., not specified; N, number; RT, radiotherapy.

Age at diagnosis and time of study reported in median years (range) or mean ± SD.

The number of patients that received pelvic radiotherapy as (part of their) cancer treatment is reported. If mentioned in the article (pelvic) radiation dosage is specified.